Emerging risk factors for atherosclerosis

Indian Heart Journal

Volumn 59, Issue 1, 2007, Pages 28-37

  John, Jim M ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; PHOSPHOLIPASE A2;

AIR POLLUTION; ANKLE BRACHIAL INDEX; ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC STRESS; CLINICAL FEATURE; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DEPRESSION; DIABETES MELLITUS; DISEASE PREDISPOSITION; ELECTRON BEAM TOMOGRAPHY; FAMILY HISTORY; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INFLAMMATION; KIDNEY FAILURE; LEUKOCYTE COUNT; METABOLIC SYNDROME X; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK FACTOR; SMOKING; SOCIAL PSYCHOLOGY; SOCIAL STATUS;

ATHEROSCLEROSIS; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 34047117478     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Centers for Disease Control and Prevention. Preventing heart disease and stroke: addressing the nation's leading killers 2004. Available at http://cdc.gov/nccdphp/aag/aag_cvd.htm.
2. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985;5:141B-49B.
3. Doelle GC. The clinical picture of metabolic syndrome. Postgrad med 2004;116:30-38.
4. Reaven GM. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycemia. Diabetes Obes Metab 2002;4:S1 3-8.
5. Bonora E, Kiechl S, Willeit J, et al. BRUNECK study. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003;26:1251-57.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. Scott CL. Diagnosis, prevention and intervention for the metabolic syndrome. Am J Cardiol 2003;92:35i-42i.
8. Denke MA. Connections between obesity and dyslipidemia. Curr Opin Lipidol 2001;12:625-28.
9. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-57.
10. Gerstein HC, Yusuf S. Dysglycemia and the risk of cardiovascular disease. Lancet 1996;347:949-50.
11. Haffner SM. Insulin resistance, inflammation and the pre-diabetic state. Am J Cardiol 2003;92:18J-26J.
12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
13. Steiner G. The use of fibrates and statins in preventing atherosclerosis in diabetes. Curr Opin Lipidol 2001;12:611-17.
14. Yusuf S, Gerstein H, Hoogwerf B, et al. for the HOPE Study investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-85.
15. Frothingham C. The relationship between acute infectious diseases and arterial lesions. Arch Intern Med 1911;8:153-62.
16. Frishman WH, Anjum I. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardiol Rev 2002;10:199-210.
17. Nicholls AC, Thomas M. Coxsackie virus infection in acute myocardial infarction. Lancet 1977;1:833-34.
18. Wood SF, Rogen AS, Bell EJ. Role of coxsackie B viruses in myocardial infarction. Br Heart J 1978;40:523-25.
19. O'Neill D, McArthur JD, Kennedy JA. Coxsackie B virus infection in coronary care unit patients. J Clin Pathol 1983;36:658-61.
20. Benditt EP, Barrett T, Macdougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 1983;80:6386-89.
21. Yamashiroya HM, Ghosh L, Yang R. Herpesviridae in the coronary arteries and aortas of young trauma victims. Am J Pathol 1988;130:71-79.
22. Hendrix MG, Salimens MMM, Van Boven CP, et al. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23-28.
23. Speir E, Modali R, Hunag ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-94.
24. Koskinen PK, Nieminen MS, Krogerus LA, et al. Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. Transpl Int 1993;6:341-47.
25. Aldous MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis 1992;166:646-49.
26. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in Helsinki Heart Study. Ann Intern Med 1992;116:273-78.
27. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268:68-72.
28. Davidson M, Kuo CC, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-33.
29. Gattone M, Iacoviello L, Columbo M, et al. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. Am Heart J 2001;142:633-40.
30. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002;288:2724-31.
31. Elkind MSV, I-Feng Lin MS, Grayston JT, et al. Chlamydia pneumoniae and the risk of first ischemic stroke. The Northern Manhattan Stroke Study. Stroke 2000;31:1521-25.
32. Wimmer ML, Sandmann-Strupp R, Saikku P, et al. Association of Chlamydia infection with cerebrovascular disease. Stroke 1996;27:2207-10.
33. Niemela S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996;73:573-75.
34. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60.
35. Cannon CP. Data from PROVE-IT trial presented at European Society of Cardiology in 2004 at Munich, Germany.
36. Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clin Cardiol 2003;26:563-68.
37. Celejermajer DS, Sorenson K, Ryalls M, et al. Impaired endothelial function occurs in systemic arteries of children with homozygous homocysteinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-58.
38. Wall RT, Harlan JM, Harker LA, et al. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980;18:113-21.
39. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
40. Stampher MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877-81.
41. Graham JM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997;277:1775-81.
42. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease:systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-32.
43. Boushey CJ, Beresford SAA, Ommen GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA 1995;274:1048-57.
44. Homocysteine Lowering Triallists Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Br Med J 1998;316:894-98.
45. Libby P, Ridker PM, Maseri A, et al. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
46. Bhatt DL. Inflammation and restenosis: is there a link? Am Heart J 2004;147:945-47.
47. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
48. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med 2003;70:634-40.
49. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42:23-30.
50. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-68.
51. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
52. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-79.
53. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
54. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Group. Lancet 1997;349:462-66.
55. Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002;85:145-49.
56. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein as a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndrome: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-65.
57. Bazzino O, Ferreiros ER, Pizarro R, et al. C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. Am J Card 2001;87:1235-39.
58. Mills R, Bhatt DL. The Yin and Yang of arterial inflammation. J Am Coll Cardiol 2004;44:50-52.
59. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
60. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-97.
61. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-74.
62. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-35.
63. Haffner SM, Greenberg AS, Weston WM, et al. Effects of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with Type 2 Diabetes. Circulation 2002;106:679-84.
64. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-56.
65. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-96.
66. Shah SH, Newby LK. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 2003;11:169-79.
67. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92:10i-18i.
68. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin or leucocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
69. Woodward M, Lowe GD, Rumley A, et al. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: the Scottish heart health study. Eur Heart J 1998;19:55-62.
70. Toss H, Lindahl B, et al. for the FRISC study group. Prognostic influence of increased fibrinogen and C-reactive proteins in unstable coronary artery disease. Circulation 1997;96:4204-10.
71. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001;155:463-66.
72. Stein JH, Rosenson RS. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 1998;137:401-05.
73. Chesney CM, Herd JA, Elam MB, et al. Niacin lowers fibrinogen in patients with peripheral artery disease [abstract]. Circulation 1996;94:S84.
74. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care 2002;25:542-49.
75. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-34.
76. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease: insights from the Framingham study. JAMA 1992;267:1253-56.
77. Bhatt DL, Chew DP, Lincoff AM, et al. Effect of revascularization on mortality associated with an elevated white cell count in acute coronary syndromes. Am J Cardiol 2003;92:136-40.
78. Yen MH, Bhatt DL, Chew DP, et al. Association between admission white blood cell count and one year mortality in patients with acute coronary syndromes. Am J Med 2003;115:318-21.
79. Gurm HS, Bhatt DL, Gupta R, et al. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J 2003;146:692-98.
80. Rajagopal V, Gurm HS, Bhatt DL, et al. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol 2004;94:190-92.
81. Uhlar CM, Whitehead AS. Serum Amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-23.
82. Banka CL, Yuan T, de Beer MC, et al. Serum Amyloid A: influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995;36:1058-65.
83. Ridker PM. Inflammation, atherosclerosis and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999;10:S9-12.
84. Liuzzo G, Biasucci L, Gallimore J, et al. Prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
85. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 2000;35:358-62.
86. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women. Circulation 2004;109:726-32.
87. Rifkin RD, Parisi AF, Folland E. Coronary calcification in the diagnosis of coronary artery disease. Am J Cardiol 1979;44:141-47.
88. Budoff MJ. Atheosclerosis imaging and calcified plaque: coronary artery disease risk assessment. Prog Cardiovasc Dis 2003;46:135-45.
89. Wong ND, Budoff MJ, Pio J, et al. Coronary calcium and cardiovascular event risk: evaluation by age- and gender-specific quartiles. Am Heart J 2002;143:456-59.
90. Raggi P, Cooil B, Callister TQ, et al. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J 2001;141:375-82.
91. Wong ND, Hsu JC, Detrano RC, et al. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol 2000;86:495-98.
92. O'Malley PG, Taylor AJ, Jackson JL, et al. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000;85:945-48.
93. Arad Y, Roth M, Newstein D, et al. Coronary calcification, coronary risk factors and atherosclerotic cardiovascular disease events. The St Francis Heart Study. J Am Coll Cardiol 2003;41:6-7.
94. Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease - a multicenter study. Circulation 1996;93:898-904.
95. Guerci AD, Spadoro LA, Popma JJ, et al. Electron beam tomography of the coronary arteries: Relationship of coronary calcium score to arteriographic findings in asymptomatic and symptomatic adults. Am J Cardiol 1997;79:128-33.
96. Vliegenthart R, Hollander M, Breteler MMB, et al. Stroke is associated with coronary calcification as detected by electron-beam CT. The Rotterdam coronary calcification study. Stroke 2003;33:462-65.
97. Cheng KS, Mikhailidis DP, Hamilton G, et al. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002;54:528-38.
98. Gariepy J, Salomon J, Denarie N, et al. Sex and topographic differences in associations between large-artery wall thickness and coronary risk profile in a French working cohort: the AXA study. Arterioscler Thromb Vasc Biol 1998;18:584-90.
99. Markus RA, Mack WJ, Azen SP, et al. Influence of lifestyle modification on atherosclerotic progression determined by ultrasonographic change in the common carotid intima-media thickness. Am J Clin Nutr 1997;65:1000-04.
100. Wagenknecht LE, D'Agostino Jr, RB, Haffner SM, et al. Impaired glucose tolerance, type 2 diabetes and carotid wall thickness: the insulin resistance atherosclerosis study. Diabetes Care 1998;21:1812-18.
101. Gnasso A, Pujia A, Irace C, et al. Increased carotid arterial wall thickness in common hyperlipidemia. Coron Artery Dis 1995;6:57-63.
102. Toikka JO, Laine H, Ahotupa M, et al. Increased arterial intima-media thickness and in-vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000;36:929-33.
103. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) study. Stroke 1995;26:386-91.
104. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
105. Salonen R, Nyyssonen K, Porkkala E, et al. Atherosclerosis Prevention Study (KAPS). A population based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1258-764.
106. Mayet J, Stanton AV, Sinclair AM, et al. The effects of anti-hypertensive therapy on carotid vascular structure in man. Cardiovasc Res 1995;30:147-52.
107. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2039-40.
108. Pope CA III, Burnett RT, Thun JM, et al. Lung cancer, cardiopulmonary mortality and long-term exposure to fine particulate air pollution. JAMA 2002;287:1132-41.
109. Verrier RL, Mittleman MA, Stone PH. Air pollution: an insidious and pervasive component of cardiac risk. Circulation 2002;106:890-92.
110. Pekannen J, Peters A, Hoek G, et al. Particulate air pollution and risk of ST-segment depression during repeated submaximal exercise tests among subjects with coronary heart disease: the exposure and risk assessment for fine and ultrafine particles in ambient air (ULTRA) study. Circulation 2002;106:933-38.
111. Pope CA III, Burnett RT, Thurston GD, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiologic evidence of general pathophysiological pathways of disease. Circulation 2004;109:71-77.
112. Antithrombotic Triallists Collaboration. Collaborative meta-analysis of randomized trials of anti-platelet therapy for the prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002;324:71-86.
113. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness and side-effects. Chest 2001;119:39S-63S.
114. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-26.
115. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43:1127-29.
116. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-55.
117. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-65.
118. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-35.
119. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-78.
120. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Am Heart J 2004;148:263-68.
121. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:18-28.
122. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trial investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation acute coronary syndromes. N Engl J Med 2001;345:494-502.
123. Strike PC, Steptoe A. Psychosocial factors in the development of coronary artery disease. Prog Cardiovasc Dis 2004;46:337-47.
124. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med 2001;345:99-106.
125. Peter R, Siegrist J. Psychosocial work environment and the risk of coronary heart disease. Int Arch Occup Environ Health 2000;73:S41-45.
126. Kuper H, Marmot M, Hemingway H. Systematic review of prospective cohort studies of psychosocial factors in the etiology and prognosis and of coronary heart disease. Semin Vasc Med 2002;2:267-314.
127. Orth-Gomer K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: the Stockholm Female coronary risk study. JAMA 2000;284:3008-14.
128. Lee S, Colditz GA, Berkman LF, et al. Care-giving and risk of coronary heart disease in US women: a prospective study. Am J Prev Med 2003;24:113-19.
129. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993;88:1973-98.
130. Appels A, Bar FW, Bar J, et al. Inflammation, depressive symptomatology and coronary artery disease. Psychosom Med 2000;62:601-05.
131. Ghiadoni L, Donald E, Cropley M, et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000;102:2473-78.
132. Hemingway H, Marmot M. Evidence-based cardiology: psychosocial factors in the etiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. BMJ 1999;318:1460-67.
133. Wulsin LR, Singal BM. Does the onset of depressive symptoms increase the risk of coronary disease? A systematic quantitative review. Psychosom Med 2003;65:201-10.
134. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med 2002;23:51-61.